| 1 | Local engineering of topological phase in monolayer MoS2显示文摘Monolayer transition metal dichalcogenides(TMDCs) with the 1 T0 structure are a new class of large-gap two-dimensional(2 D) topological insulators, hosting topologically protected conduction channels on the edges. However, the 1 T0 phase is metastable compared to the 2 H phase for most of 2 D TMDCs, among which the 1 T0 phase is least favored in monolayer MoS2. Here we report a clean and controllable technique to locally induce nanometer-sized 1 T0 phase in monolayer 2 H-MoS2 via a weak Argon-plasma treatment,resulting in topological phase boundaries of high density. We found that the stabilization of 1 T0 phase arises from the concerted effects of S vacancies and the tensile strain. Scanning tunneling spectroscopy(STS) clearly reveals a spin-orbit band gap(~60 meV) and topologically protected in-gap states residing at the 1 T0-2 H phase boundary, which are corroborated by density-functional theory(DFT) calculations.The strategy developed in this work can be generalized to a large variety of TMDCs materials, with potentials to realize scalable electronics and spintronics with low dissipation. | Zhichang Wanga Xiaoqiang Liu Jianqi Zhu Sifan You Ke Bian Guangyu Zhang Ji Feng Ying Jiang | 2019 | Science Bulletin2019，64，23： | 1 |
| 2 | Safety,immunogenicity,and preliminary efficacy of a randomized clinical trial ofomicron XBB.1.5-containing bivalent mRNA vaccine显示文摘Periodically updating coronavirus disease 19(COVID-19)vaccines that offer broad-spectrum protection is needed giventhe strong immune evasion by the circulating omicron sublineages.The effectiveness of prototype and BA.4/5-containing bivalent mRNA vaccines is reduced when XBB subvariants predominate.We initiated an observer-blinded,threearms study in 376 patients in Chinese individuals aged from 18 to 55 years old who had previously received three dosesCOVID-19 vaccine.Immunogenicity in terms of neutralizing antibodies elicited by a 30-mg dose of XBB.1.5-containingbivalent vaccine(RQ3027),a 30-mg dose of BA.2/BA.5-Alpha/Beta bivalent vaccine(RQ3025)and their precedent 30-mg Alpha/Beta(combined mutations)monovalent mRNA vaccine(RQ3013)and safety are primary and secondary endpoints,respectively.We recorded prescribed COVID-19 cases to explore the preliminary efficacy of three vaccines.RQ3027 and RQ3025 boosters elicited superior neutralizing antibodies(NAbs)against XBB.1.5,XBB.1.16,XBB.1.9.1,and JN.1 compared to RQ3013 at day 14 in participants without SARS-CoV-2 infection.All study vaccines were welltolerated without serious adverse reactions identified.The incidence rates per 1000 person-years of COVID-19 casesduring the 2nd-19th week after randomization were lowest in RQ3027.Overall,our data show that XBB.1.5-containingbivalent booster generated superior immunogenicity and better protection against newer severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variants compared to BA.2/BA.5-containing bivalent and Alpha/Beta monovalentwith no new safety concerns. | Xuanjing Yu Wei Yang Wei Li Na Wan Guanghong Yan Zumi Zhou Xiao Zhu Wei Su Yani Li Chenyu Xing Sifan Duan Houze Yu Xinshuai Zhao Chunmei Li Taicheng Zhou Dingyun You Jia Wei Zijie Zhang | 2024 | hLife2024，2，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员